Drug Profile


Alternative Names: ARQ-197

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator ArQule
  • Developer ArQule; Daiichi Sankyo Company; Istituto Clinico Humanitas; Istituto Oncologico Veneto; Kyowa Hakko Kirin; National Cancer Institute (USA); National Institutes of Health (USA); SCRI Development Innovations
  • Class Antineoplastics; Pyrrolidinones; Quinolines; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Colorectal cancer; Head and neck cancer; Mesothelioma; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • Discontinued Gastric cancer; Germ cell and embryonal neoplasms; Non-small cell lung cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 17 Feb 2017 Daiichi Sankyo and ArQule complete the phase III METIV-HCC trial in Hepatocellular carcinoma (Inoperable/Unresectable, Monotherapy, Second-line therapy or greater) in Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, New Zealand, Portugal, Spain, Sweden, Switzerland, and USA
  • 13 Jul 2016 Daiichi Sankyo completes a phase I trial for Solid tumours (in patients with hepatic impairment) in USA (NCT02150733)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top